323 related articles for article (PubMed ID: 34710276)
1. Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study.
Wu H; Yang L; Liu H; Zhou D; Chen D; Zheng X; Yang H; Li C; Chang J; Wu A; Wang Z; Ren N; Lv S; Liu Y; Jia M; Lu J; Liu H; Sun G; Liu Z; Liu J; Chen L
CNS Neurosci Ther; 2021 Dec; 27(12):1587-1604. PubMed ID: 34710276
[TBL] [Abstract][Full Text] [Related]
2. Advanced tumor electric fields therapy: A review of innovative research and development and prospect of application in glioblastoma.
Lan J; Liu Y; Chen J; Liu H; Feng Y; Liu J; Chen L
CNS Neurosci Ther; 2024 May; 30(5):e14720. PubMed ID: 38715344
[TBL] [Abstract][Full Text] [Related]
3. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.
Jo Y; Kim EH; Sai S; Kim JS; Cho JM; Kim H; Baek JH; Kim JY; Hwang SG; Yoon M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469352
[TBL] [Abstract][Full Text] [Related]
4. The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: a computational study.
Wenger C; Salvador R; Basser PJ; Miranda PC
Phys Med Biol; 2015 Sep; 60(18):7339-57. PubMed ID: 26350296
[TBL] [Abstract][Full Text] [Related]
5. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
[TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields.
Chang E; Pohling C; Beygui N; Patel CB; Rosenberg J; Ha DH; Gambhir SS
J Neurooncol; 2017 Sep; 134(2):259-268. PubMed ID: 28681243
[TBL] [Abstract][Full Text] [Related]
7. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.
Wenger C; Miranda PC; Salvador R; Thielscher A; Bomzon Z; Giladi M; Mrugala MM; Korshoej AR
IEEE Rev Biomed Eng; 2018; 11():195-207. PubMed ID: 29993870
[TBL] [Abstract][Full Text] [Related]
8. Genome-Wide Expression and Anti-Proliferative Effects of Electric Field Therapy on Pediatric and Adult Brain Tumors.
Branter J; Estevez-Cebrero M; Diksin M; Griffin M; Castellanos-Uribe M; May S; Rahman R; Grundy R; Basu S; Smith S
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216098
[TBL] [Abstract][Full Text] [Related]
9. Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy.
Pohling C; Nguyen H; Chang E; Schubert KE; Nie Y; Bashkirov V; Yamamoto V; Zeng Y; Stupp R; Schulte RW; Patel CB
Bioelectrochemistry; 2023 Feb; 149():108287. PubMed ID: 36306728
[TBL] [Abstract][Full Text] [Related]
10. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields).
Shteingauz A; Porat Y; Voloshin T; Schneiderman RS; Munster M; Zeevi E; Kaynan N; Gotlib K; Giladi M; Kirson ED; Weinberg U; Kinzel A; Palti Y
Cell Death Dis; 2018 Oct; 9(11):1074. PubMed ID: 30341282
[TBL] [Abstract][Full Text] [Related]
11. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.
Kirson ED; Dbalý V; Tovarys F; Vymazal J; Soustiel JF; Itzhaki A; Mordechovich D; Steinberg-Shapira S; Gurvich Z; Schneiderman R; Wasserman Y; Salzberg M; Ryffel B; Goldsher D; Dekel E; Palti Y
Proc Natl Acad Sci U S A; 2007 Jun; 104(24):10152-7. PubMed ID: 17551011
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields]).
Shams S; Patel CB
J Mol Cell Biol; 2022 Dec; 14(8):. PubMed ID: 35973687
[TBL] [Abstract][Full Text] [Related]
13. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
[TBL] [Abstract][Full Text] [Related]
14. First steps to creating a platform for high throughput simulation of TTFields.
Hershkovich HS; Bomzon Z; Wenger C; Urman N; Chaudhry A; Garcia-Carracedo D; Kirson ED; Weinberg U; Wassermann Y; Palti Y
Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():2357-2360. PubMed ID: 28268799
[TBL] [Abstract][Full Text] [Related]
15. Tumour treating fields therapy for glioblastoma: current advances and future directions.
Rominiyi O; Vanderlinden A; Clenton SJ; Bridgewater C; Al-Tamimi Y; Collis SJ
Br J Cancer; 2021 Feb; 124(4):697-709. PubMed ID: 33144698
[TBL] [Abstract][Full Text] [Related]
16. Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice.
Shi W; Blumenthal DT; Oberheim Bush NA; Kebir S; Lukas RV; Muragaki Y; Zhu JJ; Glas M
J Neurooncol; 2020 Jul; 148(3):489-500. PubMed ID: 32535723
[TBL] [Abstract][Full Text] [Related]
17. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Kesari S; Ram Z;
CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Compatibility of Electric Tumor Treating Fields with Key Anti-tumoral T-Cell Functions.
Simchony H; Diamant D; Ram Z; Volovitz I
Isr Med Assoc J; 2019 Jul; 21(7):503. PubMed ID: 31507132
[TBL] [Abstract][Full Text] [Related]
19. Rationale and Background on Tumor-Treating Fields for Glioblastoma.
Schwartz MA; Onuselogu L
Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S20-4. PubMed ID: 27668387
[TBL] [Abstract][Full Text] [Related]
20. Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [
Patel CB; Beinat C; Xie Y; Chang E; Gambhir SS
Neoplasia; 2021 Jan; 23(1):58-67. PubMed ID: 33221711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
